Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone CYP3A4 Inhibition Study in Healthy Males
NCT02887443Phase 1Completed
- Sponsor
- Santhera Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of idebenone in Leber hereditary optic neuropathy (LHON), sponsored by Santhera Pharmaceuticals. Primary endpoints: Area Under the Curve from dosing to last observed concentration at 13 days, Area Under the Curve extrapolated to infinity at 13 days and 5 more. Started Sep 2016; status: completed.
02
Drugs
idebenone
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT02887443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02887443.